Short Versus Long-term Levetiracetam in Brain Tumors

Launched by TATA MEMORIAL CENTRE · May 29, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating the best duration for treating seizures in patients with brain tumors using a medication called levetiracetam. Levetiracetam is often prescribed to help control seizures, but it can cause side effects like headaches and drowsiness. Currently, patients are usually treated with levetiracetam for 2 to 3 years, but researchers want to find out if a shorter treatment period could be just as effective without increasing the risk of seizures. The trial will compare two groups: one receiving a shorter course of levetiracetam and the other continuing the standard longer course.

To participate in this study, individuals must be at least 18 years old, have a diagnosed brain tumor, and have experienced seizures that are well-controlled with levetiracetam for at least six months. They should also have had surgery for their tumor within the last year. Participants can expect to be monitored closely during the study to see how their seizures respond to the different treatment durations. It's important for potential participants to discuss this opportunity with their healthcare provider to see if they meet the eligibility criteria and to understand more about what being part of the trial entails.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: • Age ≥ 18years
• • History of seizure
• • Histological diagnosis of primary brain tumor
• • Supratentorial location of primary tumor
• • Controlled on levetiracetam monotherapy for 6 months
• • Index surgery within 1 year
• • Karnofsky Performance Scale (KPS) ≥ 50
• Exclusion Criteria:
• • KPS \< 50
• • No history of seizure
• • Unclear history of seizure episodes in the past
• • Use of antiepileptics other than levetiracetam in the previous 6 months
• • No histological diagnosis
• • Progressive disease
• • Brain metastasis
• • Altered mental status with deficits in understanding or inability to consent to the study

Trial Officials